FIS Completes Major €770 Million Bond Issuance Successfully, Attracting Strong Investor Interest

FIS Successfully Completes €770 Million Bond Issuance

FIS – Fabbrica Italiana Sintetici, a leader in the production and development of active pharmaceutical ingredients (APIs), recently announced the successful completion of a notable bond issuance valued at €770 million. This transaction has drawn considerable interest from institutional investors, resulting in a significant oversubscription, demonstrating robust market confidence in FIS's operations and strategic direction.

On February 5, 2026, FIS disclosed that the bond issuance included two major components: €300 million in senior secured fixed-rate notes and €470 million in senior secured floating-rate notes. The fixed-rate notes carry an interest rate of 5.250% and were issued at face value, while the floating-rate notes are indexed to a three-month Euribor rate plus 325 basis points. Both forms of financing are set to mature in five years, by February 2031, and have been officially listed on the Luxembourg Stock Exchange's Official List and the Euro MTF Market.

In an effort to further bolster its financial stability, FIS has also increased its revolving credit facility from €80 million to €160 million. This enhancement signifies the company’s commitment to maintaining a solid liquidity position and amplifying its financial flexibility.

Given the enthusiastic response from investors, the bond issuance serves as a clear indicator of strong market confidence in FIS’s long-term strategy and financial health. Chief Executive Officer and Chairman Daniele Piergentili expressed satisfaction with the bond issuance outcome, stating, "The strong investor response reflects the market's confidence in our business model and long-term strategy. This transaction confirms our commitment to pursuing growth while ensuring a robust and flexible financial structure."

As a testament to this confidence, the company has also received upgrades in its credit ratings. Moody’s has raised FIS’s Corporate Family Rating (CFR) from B3 to B2 with a stable outlook, while Fitch Ratings improved its Issuer Default Rating (IDR) from B to B+ with a stable outlook. Standard & Poor’s has affirmed its Issuer Credit Rating (ICR) at B with a stable outlook.

To facilitate this financial venture, FIS collaborated with BNP Paribas and Goldman Sachs International, who acted as joint global coordinators and physical book runners for the issuance. Moreover, a range of banks including Banca Akros, Barclays, and J.P. Morgan participated as joint book runners, while legal consultations were provided by Latham & Watkins and Ropes & Gray, with PwC serving as the independent auditor for the issuer.

Founded in 1957, FIS has become synonymous with excellence in the pharmaceutical ingredients sector, operating across three manufacturing plants in Italy and maintaining commercial offices in North America and Japan, along with operational sites in China and India. With a workforce exceeding 2,300, FIS has cemented its position as a key player in the global pharmaceutical landscape, characterized by a commitment to Research and Development, as reflected by approximately 270 employees dedicated to such initiatives.

The accomplishment of this bond issuance not only reinforces FIS's market standing but also exemplifies its strategic foresight as it navigates the complexities of the global pharmaceutical industry. As the company continues to innovate and expand, stakeholders and investors alike will be keenly watching its next steps in this evolving market arena.